Moroccan Biologist Jinane Zouaki Joins Ibero-American Academy of Pharmacy
Rabat – Moroccan biologist Jinane Zouaki has been appointed as an academic corresponding member of the Ibero-American Academy of Pharmacy.
Her appointment marks a big milestone, as she is the first Moroccan, Arab, and African woman to receive this honor. The official ceremony took place on Tuesday at the Faculty of Pharmacy in Granada, Spain. The event gathered many scientists from Spain, Portugal, Latin America, and Morocco.
In her speech to the academy, Zouaki spoke about her history of pharmacy in Morocco. She outlined the country's recent efforts to strengthen its health sovereignty under the leadership of King Mohammed VI.
She explained that this national strategy has helped Morocco become a leading industrial hub and a strong, competitive player in both regional and international healthcare sectors.
Speaking to Morocco's state news agency MAP, Zouaki shared her pride and gratitude for joining such a prestigious institution. She said the recognition is not only a personal achievement, but also a proud moment for Moroccan women and for the country as a whole.
This recognition contributes to Morocco's scientific presence on the international stage, she added.
Originally from the northern city of Tetouan, Zouaki holds a doctorate in pharmacy. In 2022, she became the first Moroccan and African to receive the Medal of Privilege from the University of Granada, a high honor that celebrates her long journey in education and biomedical research.
Zouaki also made history as the first Moroccan to join the Royal Academy of Pharmacy of Catalonia.
During the COVID-19 pandemic, she volunteered to help medical teams. At her molecular biology lab in Saniat Rmel Hospital in Tetouan, she worked on COVID-19 testing and helped train healthcare workers. Tags: HealthMoroccopharmacy
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Morocco World
12 hours ago
- Morocco World
Moroccan Biologist Jinane Zouaki Joins Ibero-American Academy of Pharmacy
Rabat – Moroccan biologist Jinane Zouaki has been appointed as an academic corresponding member of the Ibero-American Academy of Pharmacy. Her appointment marks a big milestone, as she is the first Moroccan, Arab, and African woman to receive this honor. The official ceremony took place on Tuesday at the Faculty of Pharmacy in Granada, Spain. The event gathered many scientists from Spain, Portugal, Latin America, and Morocco. In her speech to the academy, Zouaki spoke about her history of pharmacy in Morocco. She outlined the country's recent efforts to strengthen its health sovereignty under the leadership of King Mohammed VI. She explained that this national strategy has helped Morocco become a leading industrial hub and a strong, competitive player in both regional and international healthcare sectors. Speaking to Morocco's state news agency MAP, Zouaki shared her pride and gratitude for joining such a prestigious institution. She said the recognition is not only a personal achievement, but also a proud moment for Moroccan women and for the country as a whole. This recognition contributes to Morocco's scientific presence on the international stage, she added. Originally from the northern city of Tetouan, Zouaki holds a doctorate in pharmacy. In 2022, she became the first Moroccan and African to receive the Medal of Privilege from the University of Granada, a high honor that celebrates her long journey in education and biomedical research. Zouaki also made history as the first Moroccan to join the Royal Academy of Pharmacy of Catalonia. During the COVID-19 pandemic, she volunteered to help medical teams. At her molecular biology lab in Saniat Rmel Hospital in Tetouan, she worked on COVID-19 testing and helped train healthcare workers. Tags: HealthMoroccopharmacy
Morocco World
5 days ago
- Morocco World
UM6P Partners with ANRAC to Boost Medical Cannabis Research in Morocco
Rabat – The Mohammed VI Polytechnic University (UM6P) and the National Agency for the Regulation of Cannabis-Related Activities (ANRAC) have signed a partnership agreement to work together on research into the medical and pharmaceutical uses of cannabis in Morocco. This collaboration will focus on scientific research using tested medical methods to study how cannabis can be used to treat health problems, UM6P said in a press release. The goal is to better understand the active compounds in cannabis and how they might help treat certain illnesses safely and effectively. The researchers will use tools like laboratory testing, computer modeling, and data analysis to learn more about how cannabis might work in medical treatments. They will follow strict health and safety rules throughout the research, added the statement. The agreement also includes plans to share research results with professionals in the health, pharmacy, and clinical research sectors. This is to ensure that any scientific discoveries can be used in real-life treatments under proper supervision. In addition to research, the partnership will offer training programs for doctors, pharmacists, researchers, and other healthcare professionals. These courses will teach about how cannabis works in the body, the legal rules for using it, and how to include cannabis-based treatments in patient care. A separate agreement was also signed with the African Genome Center at UM6P to support a special project on studying the local cannabis variety called 'Beldia' using advanced genetic tools. The aim is to understand this local plant better and make sure it is protected and traceable. This entire initiative is part of a bigger plan to build strong scientific knowledge about medical cannabis in Morocco. It brings together science, health care, legal standards, and ethics to develop safe and well-regulated medical uses for cannabis in the country, concluded the statement. In recent years, Morocco has undertaken several regulatory reforms to transition its long-standing cannabis economy toward a legal, controlled system. In 2021, the Moroccan parliament passed a law permitting the cultivation of cannabis strictly for medical, cosmetic, and industrial purposes. To enforce this, the government established the ANRAC, tasked with licensing farmers, processing facilities, exporters, and controlling THC thresholds, seed certification, traceability, and security across approved zones in the Rif region. Between 2022 and 2024, ANRAC issued thousands of licenses covering cultivation on more than 2,700 hectares, with legal production topping 4,000 tonnes. To incentivize transition, King Mohammed VI in August 2024 pardoned nearly 4,800 farmers convicted of illicit cannabis cultivation and helped them access the legal market.
Alalam24
6 days ago
- Alalam24
A Single Dose Could Reshape Immunity Against the Deadliest Viruses
A team of researchers from the Massachusetts Institute of Technology (MIT) and the Scripps Research Institute has developed a groundbreaking method to enhance the immune response against HIV using just a single vaccine dose, by combining two powerful immune-boosting agents. In experiments conducted on mice, results showed that the combination of traditional 'alum' and a new immune adjuvant called SMNP led to the production of more diverse and larger quantities of antibodies, compared to using the vaccine alone or with just one adjuvant. This development not only opens promising avenues for HIV prevention, but could also accelerate the creation of effective single-dose vaccines for other infectious diseases such as COVID-19 and influenza. The researchers based their study on a modified HIV protein known as MD39, used as an antigen attached to alum particles with the addition of SMNP. Following vaccination, the team observed that this combination remained stable in lymph nodes for up to a month, giving the immune system more time to build a strong and targeted response. Professor J. Christopher Love, one of the lead researchers, explained: 'This method mimics what happens during natural infection, where the antigen remains in the body for a long time, giving immune cells the opportunity to strengthen their defenses.' By analyzing B cells in the mice, researchers found that the enhanced vaccine produced a broader and greater quantity of antibodies, increasing the likelihood of generating 'broadly neutralizing' antibodies capable of targeting multiple strains of HIV. Love added: 'The more opportunities we give the immune system to explore different options, the higher the chances of producing effective antibodies against a wider range of viruses.' The study, published in Science Translational Medicine, suggests that the approach can be applied to protein-based vaccines for various diseases. Additionally, the components used are already familiar to health authorities, which could speed up regulatory approval. Love concluded: 'The true strength of this approach lies in its simplicity and effectiveness. It doesn't require new technologies, just a smarter use of existing tools to develop stronger, faster vaccines.' The research was supported by the U.S. National Institutes of Health (NIH), the Koch Institute, the Ragon Institute, and the Howard Hughes Medical Institute.
